InsiderTrades

Form 4 for ATYR aTYR PHARMA INC

Accepted 2026-02-04 00:00:00 ET · period of report 2026-02-03 · accession 0001193125-26-037996 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2026-02-04 2026-02-03 ATYR DENYES NANCY GC M - OptEx — +2,687 34.2K +9% —
D 2026-02-04 2026-02-04 ATYR DENYES NANCY GC S - Sale+OE $0.98 -1,118 33.1K -3% -$1,096
D 2026-02-04 2026-02-03 ATYR DENYES NANCY GC M - OptEx $0.00 -2,687 0 -100% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2026-02-03 M A 2,687 — 34,242 D — — (F2) Restricted stock units convert into common stock on a one-for-one basis.
2 Common Common Stock 2026-02-04 S D 1,118 $0.98 33,124 D — —
3 Derivative Restricted Stock Unit 2026-02-03 M D 2,687 $0.00 0 D — · — to — 2,687 Common Stock (F2) Restricted stock units convert into common stock on a one-for-one basis. (F4) The RSUs vest in four equal annual installments beginning on February 3, 2023, such that the RSUs fully vest on February 3, 2026. The RSUs are subject to accelerated vesting upon termination without cause upon a change of control of the Issuer.